Business
Hikma announces receipt of Warning Letter from FDA
Hikma announces receipt of Warning Letter from FDA.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 1798V Hikma Pharmaceuticals Plc 24 October 2014 \n \n\n \n \n \n \n \nLondon, 24 October 2014 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, announces that it received a Warning Letter from the U.S. Food and Drug Administration (\"FDA\") on 23 October 2014 related to the inspection of its manufacturing facility in Portugal in March 2014.\n \nIn the letter, the agency raised issues related to investigations and environmental monitoring at the facility. Hikma takes this matter very seriously and will work with the FDA to fully resolve all outstanding issues.\n \nAt this point, Hikma does not anticipate that the warning letter will impact the manufacturing or distribution of the products manufactured in its Portugal facility, and does not believe that it will impact its financial guidance for 2014.\n \nHikma remains committed to the highest standards of quality and compliance across its 27 manufacturing facilities in 11 countries.\n \nHikma will provide further updates in due course.\n \n \n \n-- ENDS --\n \n \nEnquiries\nHikma Pharmaceuticals PLC \nSusan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 7776 477050\nLucinda Baker, Deputy Head of Investor Relations +44 (0)20 7399 2765/ +44 7818 060211\n \nFTI Consulting &...